Seattle Genétics Participará en la Antibodies & Antibody Drug Conjugates . 9 - 10 April 2018 . London,UK .

Es lo que tiene ir de la mano con el Lider Mundial en ADCs.

The results from PharmaMar show that in HER2-expressing tumors, MI130004 generates a longer lasting response and inhibits significantly tumor growth providing a higher median progression free survival time in comparison with Trastuzumab ...